Skip to main content

Table 1 Clinical characteristics of the study population at baseline

From: Skin autofluorescence predicts new cardiovascular disease and mortality in people with type 2 diabetes

Characteristic New T2D Known T2D P-value
Sex (n; male/female) 569/462 656/662 0.009
Age (years) 55.0 ± 12.0 58.7 ± 10.8 < 0.001
BMI (kg/m2) 29.9 ± 5.2 30.5 ± 5.5 0.009
Waist (cm) 103 ± 13 104 ± 14 0.009
Systolic BP (mmHg) 136 ± 17 135 ± 17 0.103
Diastolic BP (mmHg) 78 ± 10 75 ± 9 < 0.001
Heart rate (bpm) 73 ± 12 74 ± 12 0.827
Creatinine (μmol/l) 75 ± 16 74 ± 17 0.052
eGFR (ml/min/1.73m2) 90 ± 16 88 ± 17 0.003
Total cholesterol (mmol/l) 5.3 ± 1.2 4.5 ± 1.0 < 0.001
HDL-cholesterol (mmol/l) 1.26 ± 0.36 1.27 ± 0.36 0.433
LDL-cholesterol (mmol/l) 3.4 ± 1.0 2.7 ± 0.9 < 0.001
Triacylglycerol (mmol/l) 1.88 ± 1.30 1.70 ± 1.11 < 0.001
Glucose (mmol/l) 7.6 ± 2.3 7.6 ± 2.1 0.747
HbA1c (mmol/mol) 49 ± 14 52 ± 11 < 0.001
HbA1c (%) 6.7 ± 1.2 6.9 ± 1.0 < 0.001
Current smoking (%) 23.7 14.4 < 0.001
Former smoking (%) 42.5 51.1 < 0.001
% w. BP-lowering therapy 35.7 63.4 < 0.001
% w. statins 20.1 63.0 < 0.001
Skin autofluorescence (AU) 2.25 ± 0.50 2.42 ± 0.54 < 0.001
SAF z score 0.34 ± 0.89 0.56 ± 0.99 < 0.001
  1. Data are presented as mean ± SD, number or %